Loading…
Viv Health, Inc. dba VIV RX was cited for misbranding compounded semaglutide and tirzepatide products in violation of sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company's website falsely represented that VIV RX was the compounder of these drug products when it was not, resulting in misleading labeling and advertising. By introducing and delivering these misbranded products into interstate commerce, the company violated section 301(a) of the FDCA, which prohibits such prohibited acts.